Primary Immunodeficiency Affecting the Innate Immune System

Abstract

Primary immunodeficiencies are a heterogeneous group of genetically inherited diseases quantitively or functionally affecting innate or adaptive immunity. The innate and adaptive arms of the immune system work synergistically to efficiently control and neutralise the wide range of pathogens that challenge vertebrates. Although at first glance innate immunity might appear primitive, innate immune cells can orchestrate discrete immune responses to different infections through the recognition of diverse pathogens by germline‐encoded pattern recognition receptors. Neutrophils, macrophages, dendritic cells, natural killer (NK) cells and NKT cells, in conjunction with natural antimicrobial agents, opsonins (as Complement) and cytokines, are critical innate components in neutralising infectious agents. Primary immunodeficiencies are understood as a state of primary lack of protective immunity. Different compartments of the innate immune system are analysed in this article to highlight their critical pathophysiological role in host defences and protective immunity.

Key Concepts:

  • The innate immune system includes epithelial and mucosal barriers, cells, natural antimicrobial product, pattern recognition receptors (PRR) and cytokines to protect the host from infections without the need of previous exposure to those microorganisms.

  • Neutrophil disorder should be suspected in patients with recurrent, severe, bacterial or fungal infections, especially those caused by unusual organisms.

  • The mononuclear phagocytes are crucial for antigen presentation and for protection against intracellular infections, especially mycobacteria.

  • Natural killer cell deficiency could involve quantitative and functional defects, in both cases showing increased susceptibility to viral infections.

  • Natural killer T (NKT) cells constitute a distinctive subpopulation of mature lymphocytes that coexpress NK (CD56) and T (CD3) cell antigens and play a central role in infectious (e.g. virus), allergic (e.g. asthma) and autoimmune diseases (e.g. hepatitis), as well as tumour control.

  • The complement system is a cascade system of more than 30 serum and membrane‐bound proteins that, when deficient, leads to impaired host defence and inappropriate inflammation.

Keywords: innate immunity; neutrophils; macrophages; NK cells; NKT cells; complement; primary immunodeficiency

Figure 1.

Schematic diagram of Complement activation.

close

References

Akbari O, Faul JL, Hoyte EG et al. (2006) CD4+ invariant T‐cell‐receptor+ natural killer T cells in bronchial asthma. New England Journal of Medicine 354(11): 1117–1129.

Ambruso DR, Knall C, Abell AN et al. (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proceedings of the National Academy of Sciences of the USA 97: 4654–4659.

de Beaucoudrey L, Samarina A, Bustamante J et al. (2010) Revisiting human IL‐12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89: 381–402.

van den Berg JM, van Koppen E and Anders A (2009) Chronic granulomatous disease: the European experience. PLoS One 4(4): e5234.

Berzofsky JA and Terabe M (2009) The contrasting roles of NKT cells in tumor immunity. Current Molecular Medicine 9(6): 667–672.

Botto M, Kirschfink M, Macor P et al. (2009) Complement in human diseases: lessons from complement deficiencies. Molecular Immunology 46(14): 2774–2783.

Cale CM, Morton L and Goldblatt D (2007) Cutaneous and other lupus‐like symptoms in carriers of X‐linked chronic granulomatous disease: incidence and autoimmune serology. Clinical and Experimental Immunology 148: 79–84.

Casanova JL and Abel L (2002) Genetic dissection of immunity to mycobacteria: the human model. Annual Review of Immunology 20: 581–620.

Cooper MA, Colonna M and Yokoyama WM (2009) Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Reports 10(10): 1103–1110.

Diana J and Lehuen A (2009) NKT cells: friend or foe during viral infections? European Journal of Immunology 39(12): 3283–3291.

Dommett RM, Klein N and Turner MW (2006) Mannose‐binding lectin in innate immunity: past, present and future. Tissue Antigens 68(3): 193–209.

Dorman SE, Picard C, Lammas D et al. (2004) Clinical features of dominant and recessive interferon‐γ receptor 1 deficiencies. Lancet 364: 2113–2121.

Etzioni A, Frydman M, Pollack S et al. (1992) Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. New England Journal of Medicine 327: 1789–1792.

Fischer A, Lisowska‐Grospierre B, Anderson DC et al. (1988) Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodeficiency Reviews 1: 39–54.

Gallin JI, Alling DW, Malech HL et al. (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. New England Journal of Medicine 348: 2416.

Goldblatt D, Butcher J, Thrasher AJ et al. (1999) Chorioretinal lesions in patients and carriers of chronic granulomatous disease. Journal of Pediatrics 134: 780.

Hanson EP, Monaco‐Shawver L, Solt LA et al. (2008) Hypomorphic nuclear factor‐kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. Journal of Allergy and Clinical Immunology 122(6): 1169–1177. e16.

Huck K, Feyen O, Niehues T et al. (2009) Girls homozygous for an IL‐2‐inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV‐associated lymphoproliferation. Journal of Clinical Investigation 119(5): 1350–1358.

Hussain N, Feld JJ, David J et al. (2007) Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology 45: 675–683.

Kang EM, Choi U and Theobald N (2010) Retrovirus gene therapy for X‐linked chronic granulomatous disease can achieve stable long‐term correction of oxidase activity in peripheral blood neutrophils. Blood 115(4): 783–791.

Lekstrom‐Himes JA, Dorman SE, Kopar P et al. (1999) Neutrophil‐specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. Journal of Experimental Medicine 189: 1847–1852.

Locci M, Draghici E, Marangoni F et al. (2009) The Wiskott‐Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Experimental Medicine 206(4): 735–742.

Lübke T, Marquardt T, Etzioni A et al. (2001) Complementation cloning identifies CDG‐IIc, a new type of congenital disorders of glycosylation, as a GDP‐glucose transporter deficiency. Nature Genetics 28: 73–76.

Lühn K, Wild MK, Eckhardt M et al. (2001) The gene defective in leukocyte adhesion deficiency II encodes a putative GDP‐fucose transporter. Nature Genetics 28: 69–72.

Malinin NL, Zhang L, Choi J et al. (2009) A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nature Medicine 15(3): 313–318.

Marciano BE, Rosenzweig SD, Kleiner DE et al. (2004a) Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114: 462.

Marciano BE, Wesley R, De Carlo ES et al. (2004b) Long‐term interferon‐gamma therapy for patients with chronic granulomatous disease. Clinical Infectious Diseases 39: 692.

Margolis DM, Melnick DA, Alling DW et al. (1990) Trimethoprim‐sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. Journal of Infectious Diseases 162: 723.

Matute JD, Arias AA, Wright NA et al. (2009) A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 114: 3309–3315.

Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449(7164): 819–826.

Mory A, Feigelson SW, Yarali N et al. (2008) Kindlin‐3: a new gene involved in the pathogenesis of LAD‐III. Blood 112(6): 2591.

Nauseef WM, Root RK and Malech HL (1983) Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency. Journal of Clinical Investigation 71: 1297.

Orange JS (2006) Human natural killer cell deficiencies. Current Opinion in Allergy and Clinical Immunology 6: 399–409.

Ott MG, Schmidt M, Schwarzwaelder K et al. (2006) Correction of X‐linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1‐EVI1, PRDM16 or SETBP1. Nature Medicine 12: 401.

Parry MF, Root RK, Metcalf JA et al. (1981) Myeloperoxidase deficiency: prevalence and clinical significance. Annals of Internal Medicine 95: 293.

Pettigrew HD, Teuber SS and Gershwin ME (2009) Clinical significance of complement deficiencies. Annals of the New York Academy of Sciences 1173: 108–123.

Rezaei N, Moazzami K, Aghamohammadi A et al. (2009) Neutropenia and primary immunodeficiency diseases. International Reviews of Immunology 28(5): 335–366.

Roesler J (2009) Carriers of X‐linked chronic granulomatous disease at risk. Clinical Immunology 130: 233.

Rosenzweig SD and Holland SM (2005) Defects in the interferon‐g and interleukin‐12 pathways. Immunological Reviews 203: 38–47.

Routes JM, Grossman WJ, Verbsky J et al. (2009) Statewide newborn screening for severe T‐cell lymphopenia. JAMA 302(22): 2465–2470.

Segal BH, Leto TL, Gallin JI et al. (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170.

Seger RA, Gungor T, Belohradsky BH et al. (2002) Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100: 4344.

Siddiqui S, Anderson VL, Hilligoss DM et al. (2007) Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clinical Infectious Diseases 45: 673–681.

Springer TA, Thompson WS, Miller LJ et al. (1984) Inherited deficiency of the Mac‐1, LFA‐1, p150,95 glycoprotein family and its molecular basis. The Journal of Experimental Medicine 160: 1901–1918.

Sun JC and Lanier LL (2009) Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? European Journal of Immunology 39(8): 2059–2064.

Svensson L, Howarth K, McDowall A et al. (2009) Leukocyte adhesion deficiency‐III is caused by mutations in KINDLIN3 affecting integrin activation. Nature Medicine 15(3): 306–312.

Thomas C, Le Deist F, Cavazzana‐Calvo M et al. (1995) Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 86: 1629–1635.

Unsworth DJ (2008) Complement deficiency and disease. Journal of Clinical Pathology 61(9): 1013–1017.

Uzel G, Tng E, Rosenzweig SD et al. (2008) Reversion mutations in patients with leukocyte adhesion deficiency type‐1 (LAD‐1). Blood 111(1): 209–218.

Walther MM, Malech HL, Berman A et al. (1992) The urologic manifestations of chronic granulomatous disease. Journal of Urology 147: 1314–1318.

Wen L, Atkinson JP and Giclas PC (2004) Clinical and laboratory evaluation of complement deficiency. Journal of Allergy and Clinical Immunology 113(4): 585–593.

Wilson JM, Ping AJ, Krauss JC et al. (1990) Correction of CD18‐deficient lymphocytes by retrovirus‐mediated gene transfer. Science 248: 1413–1416.

Winkelstein JA, Marino MC, Johnston RB Jr et al. (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79: 155.

Wynn RF, Sood M, Theilgaard‐Mönch K et al. (2006) Intractable diarrhoea of infancy caused by neutrophil specific granule deficiency and cured by stem cell transplantation. Gut Feb 55(2): 292–293.

Yokoyama WM, Kim S and French AR (2004) The dynamic life of natural killer cells. Annual Review of Immunology 22: 405–429.

Further Reading

Ochs HD, Edvard Smith CI and Puck JM (2007) Primary Immunodeficiency Diseases: A molecular and Genetic Approach, 2nd edn. New York: Oxford University Press.

Stiehm RE, Ochs HD and Winkelstein JA (2004) Immunologic Disosrders in Children and Infants, 5th edn. Philadelphia: Elsevier Saunders.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Rosenzweig, Sergio D(Feb 2011) Primary Immunodeficiency Affecting the Innate Immune System. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0001240.pub2]